Arvinas (ARVN) reported a Q2 net loss Tuesday of $0.49 per share, narrowing from a loss of $1.25 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.58 per share.
Revenue for the quarter ended June 30 was $76.5 million, up from $54.5 million a year earlier.
Analysts surveyed by Capital IQ expected $70.5 million.
Additionally, the biotechnology company said it has appointed Andrew Saik as its chief financial officer and promoted Angela Cacace to chief scientific officer and Randy Teel to chief business officer.
Price: 28.00, Change: +0.22, Percent Change: +0.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments